News

Cell-free DNA kit receives CE-IVD mark


 

Photo by Juan D. Alfonso

Blood sample collection

Vela Diagnostics’ Sentosa® SX Cell-free DNA (cfDNA) Kit has received the CE-IVD mark, which means this kit is approved for in vitro diagnostics use in the European Union.

The Sentosa® SX cfDNA Kit is intended to extract free-circulating DNA from human plasma.

The kit was developed for use in next-generation sequencing and real-time polymerase chain reaction workflows.

The kit is designed to run on the Sentosa® SX101 instrument and works with whole blood samples collected in Cell-free DNA BCT from Streck, K2, or K3 EDTA tubes.

Automated sample extraction with the Sentosa® SX cfDNA Kit takes approximately 3.5 hours. It requires 20 minutes of operator hands-on time and 4 mL of plasma from the clinical sample.

The Sentosa® SX cfDNA Kit is able to recover low-frequency DNA variants in blood, according to Vela Diagnostics.

Results from a pilot study testing the kit were presented in a poster at the AMP 2016 Annual Meeting.

Recommended Reading

Team finds no evidence that gadolinium causes neurologic harm
MDedge Hematology and Oncology
Authors’ contributions to studies often unclear
MDedge Hematology and Oncology
PTSD can persist in cancer survivors
MDedge Hematology and Oncology
Antimalarial might fight Zika virus
MDedge Hematology and Oncology
Parity laws don’t lower oral cancer drug costs for everyone
MDedge Hematology and Oncology
FDA approves IV formulation of aprepitant for CINV
MDedge Hematology and Oncology
FDA grants drug orphan designation for treatment of malaria
MDedge Hematology and Oncology
FDA approves wider use of hematology analyzer
MDedge Hematology and Oncology
Intervention improves well-being in AYAs with cancer
MDedge Hematology and Oncology
Cancer patients prefer computer-free interactions
MDedge Hematology and Oncology